Announcements Trials

Browse Landscape

Phase

Phase NA 7 Phase 3 2 Phase 2 2 Phase 4 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 118 Urinary Bladder Neoplasms 27 Carcinoma, Renal Cell 25 Kidney Neoplasms 19 Neoplasms 14 Neoplasm Metastasis 9 Breast Neoplasms 9 Non-Muscle Invasive Bladder Neoplasms 8 Prostatic Hyperplasia 5 Pain 5 Lung Neoplasms 5 Liver Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Melanoma 4 Carcinoma, Hepatocellular 4 Urologic Neoplasms 3 Stomach Neoplasms 3 Recurrence 3 Prostatic Neoplasms, Castration-Resistant 3 Multiple Myeloma 3 Kidney Diseases 3 Head and Neck Neoplasms 3 Carcinoma, Transitional Cell 3 Wilms Tumor 2 Uterine Cervical Neoplasms 2 Tobacco Use Disorder 2 Small Cell Lung Carcinoma 2 Prostatic Diseases 2 Prostate Cancer Metastatic 2 Pancreatic Neoplasms 2

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Prostate Cancer Recurrent × Genitourinary × Clear all

NCT01512472 2019-09-23

FIT

Canadian Urology Research Consortium

Phase 4 Terminated

Prostate Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡